VIVO Reddit Mentions | ChartExchange

🏢 Company Overview
Name: MediPharm Labs Corp.
Ticker Symbol: LABS.TO (Toronto Stock Exchange)
OTCQB: MEDIF (USA)
Deutsche Börse: MLZ ( GERMANY)
Headquarters: Barrie, Ontario, Canada
Founded: 2015
Industry: Pharmaceuticals / Cannabis
Website: medipharmlabs.com
MediPharm Labs specializes in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients (APIs), and advanced derivative products. The company operates in Canada, Australia, Germany, and internationally.
---
💹 Stock Snapshot (as of May 13, 2025)
Current Price: C$0.09
52-Week Range: C$0.06 – C$0.12
Market Capitalization: Approximately C$35.2 million
Shares Outstanding: 415.14 million
Dividend Yield: 0.00%
Beta: 1.13
Volatility: 11.11%
---
🧪 Business Operations
MediPharm Labs focuses on the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (APIs), and advanced derivative products. The company formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. It also provides Good Manufacturing Practice (GMP) flower sourcing, packaging, and distribution services.
In April 2023, MediPharm Labs acquired VIVO Cannabis Inc., expanding its portfolio and market reach.
📈 Investment Highlights and BIG why to invest :
1. Approaching Profitability
Adjusted EBITDA Improvement: MediPharm has shown consistent improvement in adjusted EBITDA, moving from a loss of $3.1M in Q1 2023 to a loss of $0.9M in Q1 2024, and further narrowing to a loss of $743K in Q3 2024. This trend indicates a steady path toward profitability.
2. Robust Financial Position
Debt Reduction: The company has significantly reduced its debt, bringing it down to $571K with a debt-to-equity ratio of 1.3%.
Strong Cash Reserves: As of Q3 2024, MediPharm reported a cash balance of $13 million, providing a solid buffer for operations and growth initiatives.
3. Expanding International Footprint
International Revenue Growth: International medical cannabis revenue grew by 37% year-over-year in Q3 2024, accounting for 36% of total revenues.
Global Market Penetration: The company has made significant inroads into markets like Brazil and Australia, enhancing its global presence.
4. Innovative Product Development
Dronabinol Sales: MediPharm doubled its dronabinol sales in Q2 2024, achieving total sales of $1.9M year-to-date.
New Product Launches: The company has introduced advanced non-combustible cannabis products and self-emulsifying drug delivery system (SEDDS) capsules, diversifying its product portfolio.
5. Attractive Valuation
Price-to-Sales Ratio: With a P/S ratio of 0.77, MediPharm is trading at a valuation that may be considered attractive compared to industry peers.